Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Feb 17, 2011

Premium

Title:Methods and Compositions Involving microRNA

Patent Number: 7,888,010

Filed: May 31, 2005

Lead Inventor: David Brown, Asuragen

The invention, the patent's abstract states, “concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the ... invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.”


Title: Composition and Method for In Vivo and In Vitro Attenuation of Gene Expression Using Double-Stranded RNA

Patent Number: 7,888,325

Filed: Dec. 12, 2006

Lead Inventor: Yin-Xiong Li, Georgia Research Institute

The invention, the patent's abstract states, relates to the “introduction of double-stranded RNA into cells, cell culture, organs and tissues, and whole organisms, particularly vertebrates, [that can specifically attenuate] gene expression.”


Title: Bioinformatically Detectable Group of Novel Regulatory Oligonucleotides and Uses Thereof

Patent Number: 7,888,497

Filed: May 14, 2004

Lead Inventor: Isaac Bentwich, Rosetta Genomics

The invention, the patent's abstract states, relates to a “group of novel oligonucleotides, here identified as genomic address messenger, or GAM, [oligonucleotides] and a ... group of novel operon-like polynucleotides, here identified as genomic record, or GR [polynucleotides]. GAM oligonucleotides selectively inhibit translation of known target genes, many of which are known to be involved in various diseases.”

The patent adds that “nucleic acid molecules are provided ... encoding 122,764 GAM oligonucleotides and their respective precursors, and 18,602 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.


Title: Dehydrated Chitosan Nanoparticles

Application Number: 20110033547

Filed: July 4, 2008

Lead Inventor: Jorgen Kjems, Aarhus University

The invention “relates to dehydrated nanoparticles comprising chitosan and a nucleic acid, preferably … [an] siRNA,” the patent application's abstract states. “Dehydrated nanoparticles of the invention have improved storage characteristics. The particles may be used in screening methods … [and] may also be dried onto implants for tissue engineering scaffolds, where they enable transfection of cells growing on the scaffold. Moreover, the particles have therapeutic relevance.”


Title: siRNA Detection Method

Application Number: 20110033858

Filed: Jan. 29, 2009

Lead Inventor: Kazunobu Futami, Genecare Research Institute

In the invention, “polydG is added to the terminal overhangs of an siRNA,” according to the patent application's abstract. “Next, a primer containing a polydC sequence added with a tag sequence is annealed and cDNA is synthesized by a reverse transcription reaction. Quantitative PCR is performed between a primer carrying the same sequence as the tag sequence, and a primer containing the same sequence as the siRNA sequence to be detected. The amount of siRNA of interest can be determined from a calibration curve produced using known amounts of short-chain dsDNA.”


Title: RNAi Inhibition of Influenza Virus Replication

Application Number: 20110033859

Filed: Sept. 3, 2010

Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals

“The invention relates to compositions and methods for modulating the expression of influenza viral genes, and more particularly to the down-regulation of influenza viral genes by chemically modified oligonucleotides,” the patent application's abstract states.


Title: Method for Searching Target Base Sequence of RNA Interference, Method for Designing Base Sequence of Polynucleotide for Causing RNA Interference, Method for Producing Double-Stranded Polynucleotide, Method for Inhibiting Gene Expression, Base Sequence Processing Apparatus, Program for Running Base Sequence Processing Method on Computer, Recording Medium, and Base Sequence Processing System

Application Number: 20110033860

Filed: Oct. 20, 2010

Lead Inventor: Kaoru Saigo, University of Tokyo

The invention, the patent application's abstract states, relates to “a sequence segment [that is] … searched from the base sequences of a target gene of RNA interference and, based on the search results, siRNA capable of causing RNAi is designed [and] synthesized. The 3' end base [of the sequence segment] is adenine, thymine, or uracil; the 5' end base is guanine or cytosine; a seven-base sequence from the 3' end is rich in one or more types of bases selected from the group consisting of adenine, thymine, and uracil; and the number of bases is within a range that allows RNA interference to occur without causing cytotoxicity.”


Title: Down-Regulation of Gene Expression Using Artificial microRNAs

Application Number: 20110033937

Filed: Dec. 17, 2009

Inventor: Brian McGonigle, Du Pont

The patent application, its abstract states, claims “isolated nucleic acid fragments comprising precursor miRNA, and artificial miRNAs, and their use in down-regulating gene expression.”


Title: siRNA Targeting Proto-Oncogene MET

Application Number: 20110034349

Filed: Sept. 8, 2010

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MET.”


Title: siRNA Compounds and Methods of Use Thereof

Application Number: 20110034534

Filed: July 15, 2010

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals

The invention relates to “compounds, pharmaceutical compositions comprising same, and methods of use thereof for the inhibition of certain genes, including SOX9, ASPP1, CTSD, CAPNS1, FAS, and FAS ligand,” the patent application's abstract states. “The compounds and compositions are useful in the treatment of subjects suffering from diseases or conditions and/or symptoms associated with diseases or conditions in which gene expression has adverse consequences.”


Title: Compositions and Methods for Inhibiting Expression of CD45 Gene

Application Number: 20110034537

Filed: Feb. 12, 2009

Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the CD45 gene,” according to the patent application's abstract.


Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Gastric Cancer

Application Number: 20110034538

Filed: Feb. 27, 2009

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent application's abstract states, comprises “methods and compositions for the diagnosis, prognosis, and/or treatment of gastric cancer-associated diseases.”


Title: Double-Stranded Lipid-Modified RNA Having High RNA Interference Effect

Application Number: 20110034545

Filed: March 31, 2009

Lead Inventor: Takanori Kubo, Otsuka Pharmaceutical

The invention, the patent application's abstract states, comprises a “novel double-stranded RNA that has high resistance to nuclease and cellular uptake efficiency and that can produce an excellent RNA interference effect.”

The compound is a “double-stranded lipid-modified RNA comprising a sense strand having a nucleotide sequence complementary to a target sequence in a target gene, and an antisense strand having a nucleotide sequence complementary to the sense strand,” it adds. “The double-stranded RNA [is] capable of suppressing the expression of the target gene, and the sense strand [has] a double-stranded lipid bound directly or via a linker to at least one of the first to sixth nucleotides from the 5' end.”

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.